knowledge -WSS

knowledge

author：hotspot 2025-09-30 18:01:01 - browse：5

The Amgen booth at ESMO in Madrid. Andrew Joseph/STAT

MADRID — A novel type of immunotherapy from Amgen generated strong response rates in patients with advanced small cell lung cancer, results that could lead to the approval of the drug.

The data, reported here Friday at the annual meeting of European Society for Medical Oncology, come from a Phase 2 trial of the drug, called tarlatamab. But they drew greater interest because Amgen has described the study as “potentially registrational,” and the trial results were also published Friday in the New England Journal of Medicine.

“It’s a single arm study, but the results are amazing,” said Silke Gillessen, the scientific chair of ESMO 2023 and an oncologist at the Oncology Institute of Southern Switzerland, noting that advances in small cell lung cancer have been slow to come.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

Wikipedia

explore

WSS

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

What the US credit downgrade means for the economy, your finances

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

EQRx, failed developer of low

The high personal cost of affirmative action for Black doctors

No plane should take off without an EpiPen onboard

explore

knowledge

hotspot

Bright Health sells Medicare Advantage business to Molina

After decades in use, heart stents finally beat placebo

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Study suggests Covid rebound is far more common with Paxlovid than without

Affirmative action in medical school literally saved lives

FDA reorg will put new emphasis on investigations, sources say

Novavax promises a turnaround & Lilly roils the obesity market

Healthy food access boosts outcomes in two studies

Psychedelics group wrestles with new pharma identity

The high personal cost of affirmative action for Black doctors

hotspot

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

New safety details link Apellis eye drug to rare cases of blindness

Physician groups backed by private equity giant lobby on mergers

Lawsuit alleges UnitedHealth Group unit illegally denied claims

National panel will explore requiring free Covid tests

‘Oppenheimer’ and the risks of AI in health care

explore

Wikipedia

explore

focus